Bioventus Inc. (NASDAQ:BVS) Given Consensus Rating of “Buy” by Brokerages

Shares of Bioventus Inc. (NASDAQ:BVS) have received a consensus rating of “Buy” from the five research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $14.00.

Several research firms have recently weighed in on BVS. Craig Hallum boosted their price target on Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, March 6th. Barrington Research lifted their target price on shares of Bioventus from $13.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. CJS Securities started coverage on shares of Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price on the stock. Finally, Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th.

Insider Buying and Selling

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares in the company, valued at approximately $395,523.63. This trade represents a 21.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 33.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in BVS. Anderson Financial Strategies LLC bought a new stake in Bioventus in the third quarter worth approximately $901,000. Royce & Associates LP boosted its holdings in shares of Bioventus by 15.6% during the 3rd quarter. Royce & Associates LP now owns 1,262,976 shares of the company’s stock worth $8,449,000 after buying an additional 170,900 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Bioventus by 119.7% during the 3rd quarter. Principal Financial Group Inc. now owns 55,626 shares of the company’s stock worth $372,000 after buying an additional 30,305 shares during the period. Truist Financial Corp acquired a new stake in shares of Bioventus during the 4th quarter worth approximately $93,000. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Bioventus by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 71,688 shares of the company’s stock valued at $533,000 after acquiring an additional 6,268 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Trading Up 2.1%

NASDAQ BVS opened at $9.87 on Friday. The company has a market cap of $820.69 million, a price-to-earnings ratio of 29.91 and a beta of 0.70. Bioventus has a twelve month low of $5.81 and a twelve month high of $10.76. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The business’s fifty day moving average is $9.19 and its 200 day moving average is $8.12.

Bioventus (NASDAQ:BVS) last issued its earnings results on Thursday, March 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.02. The business had revenue of $157.90 million during the quarter. Bioventus had a return on equity of 28.88% and a net margin of 4.00%.Bioventus has set its FY 2026 guidance at 0.730-0.770 EPS. As a group, sell-side analysts expect that Bioventus will post 0.76 EPS for the current fiscal year.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.